Navigation Links
HUYA Bioscience International and Zhongshan National Health Technology Park Establish Alliance
Date:7/21/2011

SAN DIEGO, July 21, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Zhongshan National Health Technology Park. The alliance will unite the strength and resources of both parties to accelerate the development of China's pharmaceutical discoveries.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Zhongshan National Health Technology Park, jointly established by the Ministry of Science and Technology, Guangdong Provincial Government and Zhongshan Municipal Government, is the first nationally designated health industrial park in China that has been built in compliance with the international standards of GLP, GMP and GCP, which qualifies the development, clinical experiments and production of new medicines.  Situated at the Torch Hi-tech Industrial Development Zone in Zhongshan, Guangdong, the park has attracted numerous national and international enterprises and has formed co-operational relationships with renowned universities worldwide.

Under the agreement, Zhongshan National Health Technology Park and HUYA will collaborate to promote new drug development. HUYA may attend project promotion events and actively participate in the annual Health and Development Zhongshan Forums at the park, or organize HUYA's partners to participate in the events. HUYA may also recommend its global pharmaceutical partners to collaborate with the park.

HUYA will have the first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical enterprises residing in the park.  HUYA will be able to internationalize select programs through HUYA's innovative co-development model and the company's worldwide pharmaceutical partners, thereby introducing qualified projects from companies in the park into global markets.

"This exciting partnership between HUYA and Zhongshan National Health Technology Park will support innovation and growth of China's pharmaceutical industry," said Clement Gingras, HUYA's CTO and COO, China. "HUYA and Zhongshan National Health Technology Park share the goal of improving the health and lives of people by providing innovative pharmaceutical products."

Conghong Yu, Director of Zhongshan Health Technology Park, commented, "With HUYA's expertise in developing innovative products in accordance with international standards, this alliance will certainly aid the park's endeavor to become a nationally and internationally known health technology industrial base."

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com.

ABOUT ZHONGSHAN NATIONAL HEALTH TECHNOLOGY PARK

Zhongshan National Health Technology Park is situated in the Torch Hi-tech Industrial Development Zone in Zhongshan, Guangdong province and covers a land area of 13.5 square km. It is the first established national-level health technology industrial base in China. The park has gathered a large number of national and worldwide companies which are engaged in the industrial fields of Chinese herbal and western synthetic medicines, healthcare products, biological engineering, health foods, medical apparatus, cosmetics and pharmaceutical packaging materials. Its total industrial output value in 2010 amounted to more than US $2.7 billion.  Zhongshan National Health Technology Park has set up its future development strategy, it will continue to grow and implement its Greater Health industrial concept to develop the business in the direction of internationalization and standardization in accordance to international practice. For more information, please visit www.zstorch.gov.cn.

CONTACT

USA:
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
+1.858.798.8800
ywang@huyabio.com

China:
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
+86.21.51323312
vxia@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Magellan Biosciences Sells TREK Microbiology Business to Thermo Fisher Scientific
2. Coronado Biosciences Files to Become a Public Reporting Company
3. SARcode Bioscience Completes $44 Million Series B Financing
4. HUYA BIOSCIENCE INTERNATIONAL ENGAGES IN PARTNERSHIP WITH LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE
5. Coronado Biosciences Closes $25.8M in Series C Financing
6. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
7. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
8. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
9. BIOSCIENCE EAST, the Life Sciences Industry Map, Highlighting Global Leaders in Healthcare Innovation, Kicks Off 5th Edition
10. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
11. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):